217 related articles for article (PubMed ID: 18056332)
1. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
Tatsumi M; Miller JH; Wahl RL
J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.
Westwood TD; Hogan C; Julyan PJ; Coutts G; Bonington S; Carrington B; Taylor B; Khoo S; Bonington A
Eur J Radiol; 2013 Aug; 82(8):e374-9. PubMed ID: 23578921
[TBL] [Abstract][Full Text] [Related]
7. The incremental value of 18F-FDG PET/CT in paediatric malignancies.
Bar-Sever Z; Keidar Z; Ben-Barak A; Bar-Shalom R; Postovsky S; Guralnik L; Ben Arush MW; Israel O
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):630-637. PubMed ID: 17048034
[TBL] [Abstract][Full Text] [Related]
8. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS
Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
12. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of optimal acquisition duration or injected activity for pediatric 18F-FDG PET/CT.
Alessio AM; Sammer M; Phillips GS; Manchanda V; Mohr BC; Parisi MT
J Nucl Med; 2011 Jul; 52(7):1028-34. PubMed ID: 21680684
[TBL] [Abstract][Full Text] [Related]
14. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI.
Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF
Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
[TBL] [Abstract][Full Text] [Related]
16. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
18. Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies.
Vicente AM; Castrejón AS; Muñoz AP; Woll PP; García AN
J Nucl Med Technol; 2010 Sep; 38(3):128-37. PubMed ID: 20807854
[TBL] [Abstract][Full Text] [Related]
19. Solid splenic masses: evaluation with 18F-FDG PET/CT.
Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
[TBL] [Abstract][Full Text] [Related]
20. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma.
Riad R; Omar W; Sidhom I; Zamzam M; Zaky I; Hafez M; Abdel-Dayem HM
Nucl Med Commun; 2010 Mar; 31(3):232-8. PubMed ID: 20032800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
